- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01324440
Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002)
March 23, 2015 updated by: Merck Sharp & Dohme LLC
A Randomized, Multicenter, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With Merck Aluminum Adjuvant or Without Merck Aluminum Adjuvant in Healthy Adults 18 to 70 Years of Age
The purpose of this study was to evaluate the safety, tolerability, and immunogenicity of the Merck 0657nI S. aureus vaccine (V710) either with or without Merck Aluminum Adjuvant (MAA).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
64
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria:
- Participant was in good physical health
- Participant was able to understand study procedures and agreed to participate in the study by providing written informed consent.
- Participant was willing and able to participate in the entire study duration planned for up to 12 months (~360 days).
- Female participants of reproductive potential were required to have a negative urine pregnancy test immediately prior to study vaccination. Female participants of reproductive potential must have used an acceptable method of birth control for 2 weeks prior to enrollment, and agreed to use an acceptable method of birth control for 1 month after vaccination.
Exclusion criteria:
- Participant suffered from a chronic skin condition that predisposed the individual to the development of chronic skin or soft-tissue infections (e.g., psoriasis, chronic granulomatous disease, atopic dermatitis).
- Participant developed a serious infection (e.g., bacteremia, pneumonia, mediastinitis) attributed to S. aureus in the 12 months prior to screening.
- Participant had a history of anaphylaxis to aluminum-containing adjuvant or other vaccine components.
- Participant had a temperature of ≥100.4ºF (≥38.0ºC), oral equivalent, within 48 hours prior to receipt of V710.
- Participant had received a live virus vaccine within 30 days prior to receipt of V710 or was scheduled to receive vaccination with a live virus vaccine within 30 days following study entry.
- Participant had received any other licensed vaccine (including non-live virus vaccines) within 14 days prior to receipt of V710 or was scheduled to receive any other licensed vaccine (including non-live virus vaccines) within 30 days following study entry.
- Participant had received V710 in a prior clinical study (Merck V710 Protocol 001).
- Participant was administered immunoglobulin or blood product within 90 days prior to receipt of V710 or was scheduled to receive such products within 30 days following study entry.
- Participant had received treatment with systemic (intramuscular, oral, or intravenous) corticosteroids or another immunosuppressive medication (e.g., calcineurin inhibitors, mycophenolate, azathioprine) or biological agents (e.g., rituximab) in the 14 days prior to receipt of V710 or was anticipated to receive such medications for a chronic medical condition during the course of the study.
- Participant had a condition that required active medical intervention or monitoring to avert serious danger to the participant's health or well-being, such as diabetes mellitus, autoimmune disease, or clinically significant chronic medical conditions that were considered progressive, including but not limited to: coronary artery disease, congestive heart failure, cardiomyopathy, progressive valvular heart disease, chronic obstructive pulmonary disease, pulmonary fibrosis, active peptic ulcer disease, chronic renal disease, chronic hepatic disease, multiple sclerosis, progressive neuropathies, or seizure disorder requiring therapy in the past 3 years.
- Participant had known or suspected impairment of immunologic function including, but not limited to, the following conditions: autoimmune disease, diabetes mellitus, endstage renal disease, hepatic insufficiency/cirrhosis, splenectomy, or human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS).
- Participant had a condition in which repeated venipuncture or injections posed more than minimal risk for the subject, such as hemophilia, other severe coagulation disorders, or significantly impaired venous access.
- Participant was pregnant or breastfeeding, or planning to conceive within the 12-month study duration period.
- Participant had clinically significant abnormalities based on the participant or physical examination.
- Participant had recent history (within the past 5 years) or current evidence of drug or alcohol abuse.
- Participant had a major psychiatric illness, including any history of schizophrenia or severe psychosis, bipolar disorder requiring therapy, or any subject with suicidal ideation within the previous 3 years.
- Participant was legally or mentally incapacitated.
- Participant had participated in another clinical study in the past 4 weeks, or participant planned to participate in a treatment-based study or study in which an invasive procedure was to be performed during the first 3 months of this study (through Day 84).
- Participant had a history of any condition which, in the opinion of the investigator, posed an additional risk for the subject or confounded the results of the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: V710 without MAA
|
Single 0.5-mL injection (30-µg) dose of V710 without MAA, intramuscularly
|
Active Comparator: V710 with MAA
|
Single 0.5-mL injection (30-µg) of V710 with MAA, intramuscularly
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With a Positive Immune Response, Defined as a Change in Antibody Level Greater Than or Equal to a 2-fold-rise at Day 14 Compared to Baseline
Time Frame: Baseline and Day 14 postvaccination
|
Immunoglobulin G (IgG) antibodies were measured by a LUMINEX(TM) assay.
|
Baseline and Day 14 postvaccination
|
Geometric Mean Antibody Concentrations (GMC)
Time Frame: Day 14 postvaccination
|
Immunoglobulin G (IgG) antibodies were measured by a LUMINEX(TM) assay.
|
Day 14 postvaccination
|
Change in Antibody Concentration (Titer) at Day 14 Compared to Baseline, Expressed as the Geometric Mean Fold-rise (GMFR)
Time Frame: Baseline and Day 14 postvaccination
|
Immunoglobulin G (IgG) antibodies were measured by a LUMINEX(TM) assay. The GMFR is the ratio of the antibody concentration at Day 14 to the antibody concentration at baseline. |
Baseline and Day 14 postvaccination
|
Number of Vaccine-related Serious Adverse Experiences
Time Frame: Up to Day 360 postvaccination
|
Investigators were instructed to determine the seriousness and causality (relatedness to test vaccine) of each AE based on criteria defined in the protocol: A serious adverse event (SAE) is any AE that:
|
Up to Day 360 postvaccination
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2006
Primary Completion (Actual)
October 1, 2007
Study Completion (Actual)
October 1, 2007
Study Registration Dates
First Submitted
February 24, 2011
First Submitted That Met QC Criteria
March 28, 2011
First Posted (Estimate)
March 29, 2011
Study Record Updates
Last Update Posted (Estimate)
April 10, 2015
Last Update Submitted That Met QC Criteria
March 23, 2015
Last Verified
March 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- V710-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Staphylococcal Infections
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
GlaxoSmithKlineCompleted
-
National Institute of Allergy and Infectious Diseases...CompletedStaphylococcal InfectionUnited States
-
Merck Sharp & Dohme LLCCompletedStaphylococcal Infection
-
National Institute of Allergy and Infectious Diseases...CompletedStaphylococcal InfectionUnited States
-
Destiny Pharma PlcCompletedStaphylococcal InfectionUnited Kingdom
-
Assistance Publique - Hôpitaux de ParisCompletedMethicillin-resistant Staphylococcal InfectionsFrance
-
National Institute of Allergy and Infectious Diseases...TerminatedStaphylococcal Aureus Infection | Recurrent Staphylococcal Infection | Invasive Staphylococcal InfectionUnited States
-
Aaron ChenJohns Hopkins University; Thrasher Research FundCompletedStaphylococcal Skin Infection | Abscess | Staphylococcal Infection | FolliculitisUnited States
-
Nantes University HospitalCompleted
Clinical Trials on V710 (30 µg) without MAA
-
RVAC Medicines (US), Inc.TerminatedCOVID-19 | Infectious DiseaseSingapore
-
BioNTech SEPfizerActive, not recruitingCOVID-19 | SARS-CoV-2 InfectionUnited States
-
RVAC Medicines (US), Inc.TerminatedCOVID-19 | Infectious DiseaseAustralia
-
Imperial College LondonGlaxoSmithKlineCompleted
-
Institut PasteurWellcome Trust; Walter Reed Army Institute of Research (WRAIR); Parexel; Bill &... and other collaboratorsActive, not recruiting
-
MedicagoCompletedRNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract DiseasesUnited States, Canada
-
Organon and CoCompleted
-
MedicagoCompletedRNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract DiseasesUnited States, Canada
-
BioDelivery Sciences InternationalPRA Health SciencesCompletedRespiratory DepressionUnited States